FDA scrutiny on nitrosamine impurities continues to shape GMP expectations. This article explains acceptable intake calculation, NDMA and NDEA limits, and how manufacturers align documentation with FDA nitrosamine risk assessment requirements to reduce inspection exposure and strengthen compliance readiness
